A third-grade teacher in Howard County, Maryland, lost four pants sizes on a GLP-1 medication. She paid $10 a month. Then her school district announced it would stop covering the drugs for weight loss, because GLP-1 claims had exploded from $485,000 in one quarter to over $3.6 million in two years. Without dropping coverage, employee premiums would have risen nearly 20%. Even with the cut, they still went up 13%.
This is the story playing out across the country right now: medications that genuinely work, priced so high that covering them threatens to collapse the insurance pools they depend on. And I want to be precise here, because precision matters. The drugs are not the problem. The pricing is.
Your Premium Subsidy for Pharma Margins
Consider what is actually happening to your paycheck. A Harvard economist estimated that about 30% of the year-over-year increase in your health insurance premium is attributable to GLP-1 drugs. In Massachusetts, Governor Healey confirmed that out of the nearly 12% premium increase last year, roughly a third was driven by GLP-1 costs. The state just voted to drop coverage for weight-loss GLP-1s for over 460,000 public workers. Eliminating the benefit is expected to bring premium growth down to an average of 7.5%, the smallest increase in years.
Read those numbers carefully. Dropping one category of drug shaves nearly five percentage points off premium growth. That is not a rounding error. That is the difference between a painful year and a manageable one for a family of four.
In one Minnesota school district, GLP-1s account for just 2% of prescriptions but a staggering 56% of total drug spending. That statistic should make you furious, not at the teachers filling those prescriptions, but at a pricing structure where a single drug class can consume more than half of an entire plan's pharmacy budget.
The EBRI simulation makes the math explicit. At current prices ($617 to $766 for a 30-day supply), covering GLP-1s pushes premiums up 5.3% to 13.8%. At a hypothetical $200 a month, the impact drops to 1% to 3.9%. The entire crisis is a pricing crisis. Nothing else.
The Cruelest Catch-22 in American Health Care
Blue Cross Blue Shield of Massachusetts reported operating losses of $380.5 million for 2025, with its chief actuary warning they are "looking at a three-year span where we may lose over $1 billion." A full one-third of their higher spending was driven by pharmaceutical outlays, much of it GLP-1 prescriptions. This is not a small insurer complaining about margins. This is the largest health plan in Massachusetts hemorrhaging cash.
So what do insurers do? They pull coverage. Starting January 1, 2026, major insurers including BCBS, Cigna, Harvard Pilgrim, and UnitedHealthcare shifted to covering these medications only for patients with Type 2 Diabetes. As of January 2026, only 13 state Medicaid fee-for-service programs cover GLP-1s for obesity treatment, down from 16 in late 2025, with states like California, New Hampshire, Pennsylvania, and South Carolina recently eliminating coverage.
And here is where the clinical evidence makes this especially painful. GLP-1 receptor agonists are among the most well-studied medications in obesity medicine. The SELECT trial (17,604 participants, randomized, placebo-controlled) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide. The STEP trials showed 15-17% body weight reduction. These are not marginal effect sizes. This is not turmeric. This is a genuine pharmacological intervention with strong evidence behind it.
Which creates the cruelest catch-22 in American health care: a medication backed by rigorous clinical trials, effective enough that people's lives measurably improve, priced so aggressively that covering it threatens the insurance system itself. Studies show that patients regain weight after discontinuation, and cardiovascular risk factors regress toward baseline, suggesting GLP-1s may need to be taken indefinitely. So we are not talking about a one-time cost. We are talking about a permanent line item for every patient, at $600 to $900 a month, forever.
The government's $245/month Medicare pricing deal is a start, but it is unclear whether the pricing agreement will extend to group health plans. Plan sponsors currently have no way to access these prices for prescriptions paid through their insurance plans. So the people most affected, working adults on employer coverage, may see no benefit at all.
I spend most of my time in this column telling people that supplements do not work, that the wellness industry sells complexity to justify its existence, that the fundamentals have not changed in 50 years. GLP-1s are different. The evidence is real. The clinical benefit is large. And watching effective, evidence-based treatment get rationed because pharmaceutical companies can charge whatever they want? That is the kind of thing that should keep you up at night.
Kai has been experimenting with cold plunges and peptides for years, and I give him grief for presenting n=1 results like conclusions. But with GLP-1s, we actually have the data. The randomized controlled trials exist. The effect sizes are large. The problem is not evidence. The problem is that the companies holding the patents have priced these drugs in a way that makes universal coverage impossible, then positioned themselves as heroes when they offer Medicare a discount. Show me the study that justifies a 30-day supply costing $766 in the United States and $100 in other countries. That study does not exist, because the pricing is not based on science. It is based on leverage.
